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associated with lipoprotein oxidation in vitro
Tiina Solakivi1, Tarja Kunnas1, Olli Jaakkola2, Jaana Renko1, Terho Lehtimäki3 and Seppo T Nikkari1,3*Abstract
Background: Oxidative modification of low-density lipoprotein (LDL) is a key event in the oxidation hypothesis of
atherogenesis. We have previously shown that HDL does not protect LDL from oxidation in vitro, but is in fact
oxidized fastest of all lipoproteins due to its rich polyunsaturated fatty acid (PUFA) composition, which is oxidation
promoting. Evidence has accumulated to show that in addition to diet, common polymorphisms in the fatty acid
desaturase (FADS) gene cluster have very marked effects on human PUFA status. There is a deletion [T/-] in the
promoter region of the Δ6 –desaturase gene (FADS2, rs 3834458), which has a direct inhibitory influence on
production of PUFA from linoleic and alpha-linolenic acid. To investigate the possible role of rs 3834458 in
lipoprotein modification, oxidation of LDL with HDL2 or HDL3 were analyzed from plasma of 58 free-living
individuals.
Results: Total eicosapentaenoic acid and arachidonic acid were significantly decreased in plasma from the 10
subjects homozygous for the deletion in FADS2 rs 3834458. When the isolated LDL and HDL2 were subjected to
Cu2+-induced oxidation, these subjects showed decreased rate of appearance (p = 0.027) and the final
concentration of conjugated dienes (p = 0.033) compared to the other genotypes. For oxidation of LDL with HDL3,
the final concentration of conjugated dienes was also significantly decreased in subjects with [−/−] compared with
[T/T] and [T/-] (p = 0.034).
Conclusion: We conclude that FADS2 genotype may play a role in peroxidation susceptibility of lipoproteins.Background
Dietary and endogenously produced fatty acids are known
to modulate the metabolism of lipids and lipoproteins and
therefore also to be involved in cardiovascular and meta-
bolic diseases [1]. Polyunsaturated fatty acids (PUFA) are
classified into two families, the n–6 and n–3 series.
Linoleic acid (18:2 n-6) and α-linolenic acid (18:3 n-3)
have become known as essential fatty acids (EFA) because
they cannot be synthesized de novo by mammals, includ-
ing humans, but are nevertheless necessary for proper
physiological functioning [1]. The human body can then
modify fatty acids by Δ6 and Δ5 desaturases and elongases
to their respective metabolites along the pathways shown
in Figure 1 to meet the metabolic needs. There is a com-
mon deletion [T/-] in the promoter region of the Δ6* Correspondence: seppo.nikkari@uta.fi
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reproduction in any medium, provided the ordesaturase gene (FADS2, rs 3834458) that has been shown
to lead to decreased plasma levels of arachidonic acid and
eicosapentaenoic acid [2,3]. Polyunsaturated fatty acids
(PUFA) may influence inflammation, as they are precur-
sors to eicosanoids [4]. Especially the eicosanoids that are
derived from arachidonic acid (20:4n–6), a metabolite of
linoleic acid (18:2n–6), have mainly pro-inflammatory ef-
fects [4]. In addition to being precursors to eicosanoids,
PUFA are readily auto-oxidized in the presence of oxygen.
This process is accelerated by the presence of trace metals
and resisted by chelating agents and antioxidants. Thus
PUFA play roles both in regulation of inflammation, and
as direct targets for peroxidation through their double
bonds that promote oxidation. PUFA play an important
role in atherosclerosis through regulation of cholesterol
transport by lipoproteins, and oxidative modification of
low-density lipoprotein (LDL) is a key event in the oxida-
tion hypothesis of atherogenesis [5]. We have previously
shown that HDL does not protect LDL from oxidation
in vitro, but is in fact oxidized fastest of all lipoproteinsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Metabolic conversions of dietary linoleic and α-
linolenic acids by Δ6 and Δ5 desaturases and elongases to
their respective metabolites (modified from [7]).
Table 1 Characteristics of the study subjects (n = 58)
Age (years) 39.3 ± 10.6
Body mass index (kg/m2) 24.4 ± 3.6
Total cholesterol (mmol/l) 5.47 ± 0.97
Triacylglycerol (mmol/l) 1.35 ± 0.71
HDL cholesterol (mmol/l) 1.65 ± 0.38
LDL cholesterol (mmol/l) 3.21 ± 0.96
Figure 2 Means (SEM) of peroxidizability index of LDL,
according to FADS2 rs 3834458 gene variants. −/−, homozygous
for the variant (deletion) allele.
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ition, which is oxidation promoting [6]. In the present
study, we tested the effect of FADS2 rs 3834458 on lipo-
protein oxidation in vitro, in plasma derived from healthy
subjects.
Results
Background characteristics of the subjects participating in
the study are shown in Table 1. The overall frequencies
for the FADS2 insertion (T)/deletion (−) genotype groups
in the study population were 0.24 for T/T, 0.59 for T/-,and 0.17 for −/−. The genotype distribution followed
Hardy–Weinberg equilibrium.
Compared with subjects with [T/T] or [T/-] in FADS2 rs
3834458, the peroxidizability index (Figure 2), the propor-
tions of plasma total arachidonic acid (20:4 n-6) (Figure 3)
and eicosapentaenoic acid (20:5 n-3) (Figure 4) were
significantly decreased in the subjects homozygous for the
deletion [−/−]. Also docosapentaenoic acid (22:5 n-3) was
similarly decreased (p = 0.016) but not docosahexaenoic
acid (22:6 n-3)(p =NS). The decreases for peroxidizability
index, arachidonic acid, eicosapentaenoic acid and doco-
sapentaenoic acid remained significant after adjusting
for age and gender (p < 0.001, p < 0.001, p = 0.008 and
p = 0.010 respectively). Plasma levels of linoleic acid and
α-linolenic acid did not correlate with the FADS2 rs
3834458 polymorphism (p =NS).
Genotypes [T/T] and [T/-] were combined for statistical
analyses of the oxidation study since they showed similar
Figure 3 Means (SEM) of plasma arachidonic acid proportions,
according to FADS2 rs 3834458 gene variants. −/−, homozygous
for the variant (deletion) allele.
Figure 4 Means (SEM) of plasma eicosapentaenoic acid (EPA)
proportions according to FADS2 rs 3834458 gene variants. −/−,
homozygous for the variant (deletion) allele.
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tures of isolated LDL and HDL2 were subjected to Cu
2+-in-
duced oxidation, the subjects with [−/−] showed decreased
rate of appearance (p = 0.027) and the final concentration
(P = 0.033) of conjugated dienes, compared with [T/T] and
[T/-] (Table 2). The findings remained significant after
adjusting for age and gender. When isolated HDL3 was
subjected to Cu2+-induced oxidation with LDL, a similar
trend was observed in oxidation rate, but only the final
concentration of conjugated dienes was significantly de-
creased in subjects with [−/−] compared with [T/T] and
[T/-] (p = 0.034; p = 0.031 after adjusting for age and gen-
der) (data not shown).
Discussion
The overall frequencies for the FADS2 rs 3834458 inser-
tion (T)/deletion (−) genotype groups in the study popula-
tion were 0.24 for T/T, 0.59 for T/-, and 0.17 for −/−.
These differed from the KOALA study (the Netherlands)
and the LISA study (Germany), where the frequencies
were 0.46, 0.43, 0.11 and 0.47, 0.44, 0.09, respectively [8].
In both of these studies, the FADS2 gene rs3834458 was
typed with MALDI-TOF-MS. On the other hand, in sub-
jects from Costa Rica, by using a variation of the allele-
specific assay, the corresponding frequencies were 0.29,
0.47 and 0.23 [3], which are more in line with our results.
The difference in frequency in our study compared to the
KOALA and LISA studies might be due to a different
method of analysis, or to a difference in the study popula-
tions [8]. However, prior to analysis, we confirmed the
products of our PCR primers to be specific for FADS2 rs
3834458 insertion comparing the sequenced products
with the GenBank database.
Long-chain n-3 and n-6 polyunsaturated fatty acids are
formed from the EFA linoleic acid and alpha-linolenic acid
by sequential desaturation and elongation (Figure 1). There
is a decreased promoter activity in FADS2 rs3834458 for
this function [2]. As expected, the fatty acid profile of the
plasma from subjects homozygous for the FADS2 rs
3834458 deletion [−/−] differed substantially from that ofTable 2 Kinetic parameters of LDL + HDL2 oxidation in
healthy subjects according to FADS2 genotype
Genotype TT and T – – – P P*
N 48 10
LDL + HDL2
Lag time (min) 56.1 ± 6.2 57 ± 5.4 0.764 0.296
Rate (μmol/l/min)a 0.685 ± 0.075 0.656 ± 0.085 0.027 0.027
Max (nmol/mg)b 777 ± 50 735 ± 74 0.033 0.034
Values are mean ± SD. a Rate means maximal formation rate of conjugated
dienes during oxidation. Calculation of the diene concentration is based on
ε234 nm = 29500 l/mol/cm of the conjugated dienes.
b Max is the maximal
amount of dienes produced per mg of LDL protein.
*; adjusted for age and gender.
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cosapentaenoic acid (20:5 n-3), docosapentaenoic acid
(22:5 n-3) and arachidonic acid (20:4 n-6) were significantly
decreased. These findings are in line with earlier observa-
tions [3,8,9]. However, only about 8% of the dietary linoleic
acid / α-linolenic acid go through the elongase/desaturase
biosynthetic pathway to eicosapentaenoic acid and conver-
sion to docosahexaenoic acid is extremely low (<0.1%) [10].
This may put into perspective the clinical relevance of the
genotype findings. Moreover, the type of fat in the diet is
reflected in serum fatty acids [11] and we had no know-
ledge on the habitual diet of the participants, which could
have influenced the outcome. In spite of this limitation, it
seems unlikely that the subjects homozygous for the
FADS2 rs 3834458 deletion [−/−] would have had a diet
that differed substantially from that of the other genotypes.
Earlier studies have shown that there are several intrin-
sic properties of lipoproteins that can affect their suscepti-
bility to oxidation. Especially in supplementation studies,
lipoprotein antioxidant content and fatty acid composition
[12-15] have been shown to have an impact on oxidation
parameters. We analyzed the fatty acid compositions of
LDL, HDL2 and HDL2 particles and united the informa-
tion in the fatty acid profiles into a single term – the
peroxidizability index – which describes the combined re-
activity of fatty acids towards reactive oxygen species [16].
The results of our experiments suggest that proportions of
polyunsaturated fatty acids affected by FADS2 are related
to the peroxidation index, oxidation rate and the amount
of dienes formed during in vitro oxidation. This may also
have implications in vivo since – although PUFA are con-
sidered to be beneficial in many aspects – they also have
inflammatory and pro-oxidant properties.
Conclusions
In summary, we report that compared to subjects with [T/
T] or [T/-] in FADS2 rs 3834458, the formation of arachi-
donic acid and EPA were significantly decreased, as
reported previously. What is new is that the theoretical
peroxidizability index was also decreased in lipoproteins
from these individuals. Consequently, when the isolated
LDL and HDL were subjected to Cu2+-induced oxidation,
the subjects with [−/−] showed decreased rate of appear-
ance and the final concentration of conjugated dienes,
compared to [T/T] and [T/-]. Thus, FADS2 genotype may
play a role in peroxidation of lipoproteins.
Methods
Subjects
61 healthy subjects from the personnel and medical stu-
dents of the Department of Medical Sciences of Tampere
University and Tampere University Hospital volunteered.
The age range of the subjects was 20 to 58 years. 33 were
women and 28 were men. All participants filled in aquestionnaire, where emphasis was given to their health
status (diseases and use of medication) in addition to
health related behaviour (smoking, use of alcohol and
vitamins). The results of three of the participants were
later removed from analysis because of reported bowel
diseases. Thus, 58 subjects remained; 32 women and 26
men. All participants gave their written consent to the
study. The study protocol was approved by the ethics
committee of the Tampere University Hospital.
Blood Samples
Fasting (12 h) blood samples were taken into suitable
tubes (Vacuette, Greiner) from the antecubital vein in a
sitting position after a 15-min rest using minimal stasis.
Samples for the analysis of lipids, extraction of DNA and
isolation of lipoproteins were taken into pre-chilled EDTA
tubes, which were immediately placed in ice. Plasma was
separated after centrifugation (Heraeus, 2000xg, +4°C).
EDTA plasmas for isolation of lipoproteins were sup-
plemented with sucrose (0.6% w/v final concentration).
This procedure has been shown to preserve LDL from
oxidation for at least two months and the oxidation curve
does not differ from that of a fresh sample [17]. Lipids
were analysed as described [6]. All samples were kept fro-
zen at −70°C until analyzed.
DNA isolation, FADS2 genotyping and Sequencing
Genomic DNA was extracted from peripheral blood leu-
kocytes using a commercial kit according to the manufac-
turer’s instructions (Qiagen, Hilden, Germany). Insertion/
deletion of T in FADS2 was genotyped with the use of 2-
allele specific primers designed in such a way that the only
difference between them was the insertion site at the very
last nucleotide of their 3´ends. Prior to final genotyping
the amplified products were confirmed by sequencing 8
clones from an individual who proved to be homozygous
for insertion and 16 randomly selected clones from an-
other one who was homozygous for deletion variant. After
amplification, PCR products were run in 2% agarose gel
electrophoresis. Two parallel PCRs were performed for
each DNA sample. These contained primers: 5´CTAG
GTGACGCCCTTCCTT 3´ (right), and either 5´GAGG
TTCCGCAATTCTTTTCT 3´ (left) or 5´GAGGTTCC
GCAATTCTTTTC 3´ (left). Amplification conditions
were; 94°C 15 min, followed by 32 cycles of 94°C, 63°C
and 72°C for 30 s each and final extension at 72°C for
5 min. For control sequencing, PCR was performed using
primers D6Dsense (5’-GCC AGT TCC TCA TCG CCC
CC-3’) and D6Dantisense (5’-TCC CTT CCC CAT GCT
GCC TG-3’) [2]. PCR conditions consisted of 15 min at
94°C, followed by 33 cycles at 94°C 1 min, 69°C 1 min,
72°C 2 min, and final extension 72°C for 30 min. The
primers produced fragments of 1059 bp. Prior to sequen-
cing, amplified PCR products were cloned by using the
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ABI PRISM 3130 Genetic Analyzer (Applied Biosystems)
and BigDye Terminator Cycle sequencing chemistry (Ap-
plied Biosystems) using M13(−20)F and M13R primers for
determining DNA sequences on both strands. The partial
16S rDNA sequences of approximately 600 bp were edited
and aligned using the Chromas 2.31 (Technelysium) and
ClustalW sequence analysis software, and compared with
those in the GenBank database by using the BLAST search
tool (National Center for Biotechnology Information;
http://www.ncbi.nlm.nih.gov/BLAST/).
Isolation of lipoproteins and plasma fatty acid
composition
Lipoproteins were fractionated by isopycnic density gra-
dient ultracentrifugation using a Beckman SW40 Ti rotor
in a Beckman L60 centrifuge (36000 rpm, 40 hours,
10°C) as previously described [6]. The fatty acid compo-
sitions were analyzed by capillary gas–liquid chro-
matography [6,7]. From fatty acid compositions, the
peroxidizability index was calculated: (PI) = [(Σ mol%
monoenoic FAs × 0.025) + (Σ mol% dienoic FAs × 1) +
(Σ mol% trienoic FAs × 2) + (Σ mol% tetraenoic FAs × 4) +
(Σ mol% pentaenoic FAs × 6) + (Σ mol% hexaenoic
FAs × 8)] [14].
Oxidation of lipoproteins
The susceptibility of mixtures of LDL and HDL2 or
HDL3 subtractions to in vitro copper-catalyzed oxidation
was assessed by continuously monitoring the production
of conjugated dienes at 234 nm, as previously described
[6,18]. Oxidation was started by adding 10 μl of CuSO4
to a final concentration of 1.65 μM Cu2+. The spectro-
photometer was computer-operated (UVWinlab 2.1).
This program also collected the absorbance data at 2-
min intervals during the oxidation. Several characteristic
oxidation indices were obtained from the resulting ab-
sorbance versus time curves [17,19].
Data analysis
Results are expressed as mean ± SD unless otherwise
stated. Statistical comparisons were made by Univariate
General Linear Model, T-test and Mann–Whitney test
using IBM SPSS software, version 20. Due to skewed dis-
tribution, plasma values of eicosapentaenoic acid and kin-
etic parameter of LDL +HDL2 oxidation rate were used as
their logarithms but reported as their original results. A p
value <0.05 was taken to be statistically significant.
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